Navigation Links
Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
Date:6/11/2008

infusion daily for five days of a 21-day cycle in patients with advanced pancreatic cancer who have progressed on gemcitabine or a gemcitabine-containing regimen.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.

Forward-Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements related to the therapeutic and commercial potential of PX-12; future clinical development plans; the details of clinical trials; and the anticipated future size of the market for PX-12. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, and the safety and efficacy of PX-12. There can be no guarantee that the results of earlier trials will be predictive of
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncothyreon to receive milestone payment
2. Oncothyreon Reports First Quarter 2008 Financial Results
3. Oncothyreon files investigational new drug application for PX-866 oncology compound
4. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
5. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
6. Oncothyreon announces effectiveness of shelf registration statement
7. Oncothyreon announces issuance of patent for PX-867
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon reports full year and fourth quarter 2007 financial results
10. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
11. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Jose, California (PRWEB) September 30, 2014 ... measure the level of each type of cholesterol carrier ... since the presence of excessive cholesterol levels in the ... a precursor condition to heart attack and other cardiovascular ... fatality worldwide, therefore testing for cholesterol levels on a ...
(Date:9/30/2014)... Hungary , September 30, 2014 ... and intuitive browsing of chemistry in documents ... chemistry software solutions and consulting services for life ... chemical information and generate Markush structures from documents. ... an organizations intellectual property, however generating and understanding ...
(Date:9/30/2014)... 30, 2014  KemPharm, Inc., a clinical-stage specialty ... of proprietary new molecular entity (NME) prodrugs, announced ... Office (USPTO) issued U.S. Patent No. 8,816,083 to ... Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates ... Thereof." The patent, which extends through ...
(Date:9/30/2014)... iLab Solutions announced the results of its ... on core facility operations, growth and utilization as well ... In its 4th year running, a number of long-term ... decrease in the percentage of revenue that comes from ... constraints of this trend. When asked, “What are your ...
Breaking Biology Technology:Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3
... ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... Technologies Business Unit Into New North American... -- SOUDERTON, Pennsylvania, October 13, 2010 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
... Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia... -- SAN FRANCISCO, October 13, ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Biology Technology:550 People Across Europe Will Die Today From a Preventable Lung Disease 2550 People Across Europe Will Die Today From a Preventable Lung Disease 3550 People Across Europe Will Die Today From a Preventable Lung Disease 4550 People Across Europe Will Die Today From a Preventable Lung Disease 5550 People Across Europe Will Die Today From a Preventable Lung Disease 6550 People Across Europe Will Die Today From a Preventable Lung Disease 7550 People Across Europe Will Die Today From a Preventable Lung Disease 8550 People Across Europe Will Die Today From a Preventable Lung Disease 9Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 2Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 3Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 4Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 5Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 6Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 7Almac Successfully Moves its Clinical Technologies Business Unit Into New North American Headquarters 8Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 2Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 3Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 4Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 5Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 6Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 7Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 8Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 9
(Date:9/29/2014)... a new Food and Brand Lab pilot study, published ... in the National School Lunch Program (NSLP) by 9% ... , Chefs Move to Schools (CMTS), an initiative of ... in order to provide nutrition instruction to students and ... A CMTS event was held in an Upstate New ...
(Date:9/29/2014)... world,s needs to make cheaper and more effective ... efficient catalytic materials and processes must be developed. ... State University, is tackling this problem with the ... Science Foundation. , The nearly $1.5 million project, ... Cascade Reactions," was to Eranda Nikolla, Ph.D., assistant ...
(Date:9/29/2014)... five-year, $6 million grant for clinical research and ... of safe and effective treatments for cocaine addiction. ... Institutes of Health, National Institute on Drug Abuse, ... for Cocaine Use Disorder to oversee preclinical and ... moving forward with more expensive large-scale clinical trials. ...
Breaking Biology News(10 mins):Chefs move to schools can increase school meal participation and vegetable intake among students 2Wayne State research aims to develop new, more efficient catalytic materials 2New VCU center to target cocaine addiction 2
... Theres more to biofuels than the food vs. fuel debate ... And so Steven Fales, a professor of agronomy ... Iowa States Bioeconomy Institute, organized and moderated a three-hour symposium ... American Association for the Advancement of Science in Boston. ...
... theory into practice to manage complex and closely linked ... challenge, but one NOAA researcher Anne Guerry says can ... value of our ocean resources. Guerry will ... people obtain from ecosystems, in managing marine resources in ...
... This release is available in French . , ... the University of Toronto to rev up the production of stem ... cells and embryonic stem cells. The end products are blood and ... they form beating tissue. To do this, he has ...
Cached Biology News:Iowa Staters talk biofuels, healthy oils and 'pharma crops' at AAAS meeting 2Can Dungeness crab and eelgrass help improve management of our marine resources? 2From stem cells to organs: The bioengineering challenge 2
Rabbit Anti-JNK1/SAPK pan, Polyclonal Antibody...
Low melting point. Ideally suited for in gel enzymatic reactions. Gelling temp. 24-28C Melting temp. 65C. EEO 0.12 Resolution 0.5-20 kb; Rnase/Dnase: none detected....
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
Biology Products: